Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 23Phase 1/2 8Phase 3 6Phase EARLY_PHASE1 2Phase 4 2Phase 2/3 1

Status

Active not recruiting 3Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Gynecologic 1

Conditions

Ovarian Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 6Breast Neoplasms 6Metastatic Castration-resistant Prostate Cancer 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Hematologic Neoplasms 1HER2-ve Metastatic Breast Cancer 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 149Docetaxel 139Paclitaxel 127Trastuzumab 120Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × olaparib × Clear all
NCT06966700 2026-06-01

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme LLC

Phase 3 Recruiting
2,400 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02032823 2026-05-06

OlympiA

AstraZeneca

Phase 3 Active not recruiting
1,837 enrolled 20 charts 1 FDA
Breast

Breast Neoplasms

NCT04421963 2026-04-16

ROSY-O

AstraZeneca

Phase 3 Active not recruiting
185 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

AstraZeneca

Phase 3 Active not recruiting
1,902 enrolled
Breast

Breast Neoplasms

NCT07486687 2026-03-20

PLANET

The Netherlands Cancer Institute

Phase 3 Not yet recruiting
1,000 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02000622 2026-02-13

OlympiAD

AstraZeneca

Phase 3 Completed
302 enrolled 26 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡